IL17A and rheumatoid arthritis: IL-17 appears to be a master regulator of proinflammatory responses in both allergic and autoimmune inflammatory diseases and, thus, it is currently a major interest of the pharmaceutical industry [86], as evidenced by the new therapies targeting this cytokine, including the anti-IL-17A monoclonal antibody, ixekizumab [87,88] and the anti-IL-17-receptor monoclonal antibody brodalumab [14], both of which have been evaluated in Phase II clinical trials to treat RA and psoriasis.